Location History:
- NY, NY (US) (2009)
- New York, NY (US) (1996 - 2011)
- Vienna, AT (2017)
Company Filing History:
14 out of 525 
7 out of 559 
4 out of 1,521 
Years Active: 1996-2017
Title: Elisabeth Stockert: Innovator in Cancer Research
Introduction
Elisabeth Stockert is a prominent inventor based in New York, NY, whose contributions to cancer research have led her to acquire 28 patents. Her work focuses on the development of specific binding proteins, particularly antibodies, that target aberrant forms of the epidermal growth factor receptor (EGFR).
Latest Patents
Among her latest patents, one notable invention involves specific binding members, especially antibodies and their active fragments. These antibodies uniquely recognize an aberrant post-translationally modified form of EGFR, which allows them to selectively bind to cancer cells while sparing normal cells. The invention highlights a novel antibody, named antibody 806, whose variable heavy and light chain sequences are clearly defined. Additionally, she has developed isolated nucleic acid molecules encoding cancer-associated antigens, which provoke immune responses in patients, showcasing her commitment to advancing cancer immunotherapy through innovative solutions.
Career Highlights
Throughout her career, Elisabeth has been affiliated with the Ludwig Institute for Cancer Research Limited, where she has made significant advancements in cancer research and therapy. Her groundbreaking inventions have not only expanded the understanding of cancer biology but have also provided new avenues for treatment options.
Collaborations
Elisabeth has collaborated with notable colleagues such as Lloyd J. Old and Yao-tseng Chen. Their collective efforts have contributed valuable insights into the mechanisms of cancer and the development of targeted therapies, further amplifying the impact of her work in the scientific community.
Conclusion
Elisabeth Stockert's innovative contributions to the field of cancer research underscore her role as a dedicated inventor. With her 28 patents and ongoing commitment to understanding and combating cancer, she continues to be a vital figure in the scientific landscape, paving the way for future advancements in medical treatments.